ABSTRACT
HIV-exposed uninfected (HEU) children may have altered immune regulation and poorer neurodevelopment outcomes compared to their HIV-unexposed (HU) counterparts. However, studies investigating the association of maternal and infant inflammation with neurodevelopment in HEU children are limited and longitudinal data are lacking. This study investigated serum inflammatory markers in HIV-infected vs. uninfected women during pregnancy and in their children, as well as associations with neurodevelopmental outcomes at two years of age in an African birth cohort study. A sub-group of mother-child dyads from the Drakenstein Child Health Study had serum inflammatory markers measured at ≈26 week’s gestation (n=77 HIV-infected mothers; n=190 HIV-uninfected mothers), at 6-10 weeks (n=63 HEU infants and n=159 HU infants) and at 24-28 months (n=77 HEU children and n=190 HU children). Serum inflammatory markers [granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ), interleukin IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, tumor necrosis factor-α (TNF-α), neutrophil gelatinase-associated lipocalin (NGAL) and metalloproteinase-9 (MMP-9)] were analyzed with a multiplex bead array and ELISA assays. The Bayley Scales of Infant and Toddler Development, third edition, was used to assess neurodevelopment at 24-28 months. After correcting for multiple comparisons, HIV-infection during pregnancy was associated with lower serum levels of inflammatory markers in mothers at 26 weeks gestation (GM-CSF and MMP9, p<0.05) and HEU children at 6-10 weeks (IFN-γ and IL-1β, p<0.01), and at 24-28 months (IFN-γ, IL-1β, IL-2 and IL-4, p<0.05) compared to HIV-uninfected mothers and HU children. In HEU infants at 6-10 weeks, inflammatory markers (GM-CSF, IFN-γ, IL-10, IL-12p70, IL-1P, IL-2, IL-4, IL-6 and NGAL, all p<0.05) were associated with poorer motor function at two years of age. This is the first study to evaluate the associations of follow-up immune markers in HEU children with neurodevelopment. These findings suggest that maternal HIV infection is associated with immune dysregulation in mothers and their children through two years of age. An altered immune system in HEU infants is associated with poorer follow-up motor neurodevelopment. These data highlight the important role of the immune system in early neurodevelopment and provide a foundation for future research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Drakenstein Child Health Study was funded by the Bill & Melinda Gates Foundation (OPP 1017641), Discovery Foundation, Medical Research Council South Africa, National Research Foundation South Africa, CIDRI Clinical Fellowship and Wellcome Trust (204755/2/16/z). DJS, HJZ, KAD and WB are supported by the SA Medical Research Council (SAMRC). CJW is supported by the Wellcome Trust through a Research Training Fellowship [203525/Z/16/Z]. WB is supported by the SAMRC, through its Division of Research Capacity Development under the Bongani Mayosi National Health Scholars programme. PJWN is supported by the National Alliance for Research on Schizophrenia and Depression Young Investigator Grant (No. 25199) and Scott-Gentle Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
On request
